Axitinib Oral Tablet

DRUG2 trials

Sponsors

Scottish Clinical Trials Research Unit, Consorzio Oncotech

Conditions

Metastatic Renal Cell CarcinomaNon-metastatic Renal Cell CarcinomaRenal Carcinoma MetastaticRenal Cell Carcinoma

Phase 2

Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion

CompletedNCT03494816

Scottish Clinical Trials Research UnitMetastatic Renal Cell Carcinoma, Non-metastatic Renal Cell Carcinoma, Renal Cell Carcinoma

Start: 2017-12-15End: 2020-06-10Updated: 2021-06-30

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

Consorzio OncotechRenal Carcinoma Metastatic

Start: 2020-10-07End: 2024-10-31Target: 75Updated: 2021-01-06

Related Papers

Updated results of the Tide-A study evaluating avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients with metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology2025-02-10

‘Case of the Month’ from Addenbrooke's Hospital, Cambridge, <scp>UK</scp> : surgery after near complete response to combined immunotherapy and tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma with inferior vena cava tumour thrombus

British Journal of Urology2024-07-16

A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA).

2022-06-2354 citations

Investigating treatment effects in the microenvironment of renal cell cancer with venous tumor thrombus: Translational analysis of the NAXIVA trial.

Journal of Clinical Oncology2022-02-16

NAXIVA: A phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer (RCC) with venous invasion.

Journal of Clinical Oncology2021-02-208 citations